Patents by Inventor Dirk Seegert

Dirk Seegert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
    Patent number: 10888555
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 12, 2021
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Wätzig, Dirk Seegert
  • Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
    Patent number: 10758552
    Abstract: The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 1, 2020
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Wätzig, Dirk Seegert
  • PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA
    Publication number: 20200009124
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Waetzig, Dirk Seegert
  • Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
    Patent number: 10426765
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 1, 2019
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Waetzig, Dirk Seegert
  • Sgp130/Fc dimers
    Patent number: 9573989
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: February 21, 2017
    Assignee: Conaris Research Institute AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE FOR BENEFICALLY INFLUENCING BLOOD LIPID LEVELS BY MODIFYING THE INTESTINAL MICROBIOTA
    Publication number: 20170027924
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
    Type: Application
    Filed: December 12, 2014
    Publication date: February 2, 2017
    Applicant: Conaris Research Institute AG
    Inventors: Georg Wätzig, Dirk Seegert
  • A PHARMACEUTICAL COMPOSITION CONTAINING COMBINATIONS OF NICOTINAMIDE AND 5-AMINOSALICYLIC ACID FOR BENEFICIALLY INFLUENCING THE INTESTINAL MICROBIOTA AND/OR TREATING GASTROINTESTINAL INFLAMMATION
    Publication number: 20160317557
    Abstract: The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Application
    Filed: December 12, 2014
    Publication date: November 3, 2016
    Applicant: CONAIRS RESEARCH INSTITUTE AG
    Inventors: Georg Watzig, Dirk Seegert
  • SGP130/FC DIMERS
    Publication number: 20150361157
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: April 17, 2015
    Publication date: December 17, 2015
    Inventors: Georg H. Wätzig, Dirk Seegert
  • sgp130/Fc dimers for treatment of inflammatory disease
    Patent number: 9034817
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 19, 2015
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA
    Publication number: 20150126462
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 7, 2015
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Waetzig, Dirk Seegert
  • sgp130/Fc dimers
    Patent number: 8895012
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: November 25, 2014
    Assignee: Conaris Research Institute AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • SGP130/FC DIMERS
    Publication number: 20140178378
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 26, 2014
    Applicant: Conaris Research Institute AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • Optimized nucleotide sequences encoding sgp130
    Patent number: 8206948
    Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 26, 2012
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Georg Wätzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
  • Soluble GP130 molecule variants useful as a medicament
    Patent number: 7851182
    Abstract: A polypeptide-dimer built of two identical monomeric fragments comprising the domains 1 to 3 of the extracellular (soluble) part of glycoprotein (gp)130 and a certain polypeptide spacer are described, which are covalently linked with each other and which bear significant advantages concerning their production rate in host cells, their improved purification and their potential to bind to IL-6/soluble IL-6 receptor complexes. Furthermore, a pharmaceutical composition containing said dimeric molecule and various medical uses are described.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: December 14, 2010
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Georg H. Waetzig
  • SGP130/FC DIMERS
    Publication number: 20100028367
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: June 29, 2007
    Publication date: February 4, 2010
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • PEGylated soluble GP130-dimers useful as a medicament
    Patent number: 7629147
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: December 8, 2009
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
  • SOLUBLE GP130 MOLECULE VARIANTS USEFUL AS A MEDICAMENT
    Publication number: 20090227499
    Abstract: A polypeptide-dimer built of two identical monomeric fragments comprising the domains 1 to 3 of the extracellular (soluble) part of glycoprotein (gp)130 and a certain polypeptide spacer are described, which are covalently linked with each other and which bear significant advantages concerning their production rate in host cells, their improved purification and their potential to bind to IL-6/soluble IL-6 receptor complexes. Furthermore, a pharmaceutical composition containing said dimeric molecule and various medical uses are described.
    Type: Application
    Filed: December 22, 2006
    Publication date: September 10, 2009
    Inventors: Dirk Seegert, Georg H. Waetzig
  • PEGylated soluble gp130-dimers useful as a medicament
    Patent number: 7534862
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: May 19, 2009
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
  • PEGYLATED SOLUBLE GP130-DIMERS USEFUL AS A MEDICAMENT
    Publication number: 20080227155
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: February 5, 2008
    Publication date: September 18, 2008
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
  • Optimized Nucleotide Sequences Encoding Sgp 130
    Publication number: 20080199906
    Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
    Type: Application
    Filed: August 26, 2005
    Publication date: August 21, 2008
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Dirk Seegert, Georg Watzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John